Beacon Therapeutics

Beacon Therapeutics, building on AGTC's foundation established in 1999, is a clinical-stage biotechnology company using a proprietary gene therapy platform to develop treatments for severe ophthalmic diseases. Its pipeline targets inherited orphan retinal diseases like X-linked Retinitis Pigmentosa (XLRP) and Achromatopsia (ACHM), alongside prevalent conditions such as dry Age-related Macular Degeneration (dry AMD). The company employs advanced Adeno-Associated Virus (AAV) technology for targeted delivery and aims to restore vision and transform patient lives by addressing the root genetic causes.